Blueprint Medicines Corp BPMC:NASDAQ

Last Price$72.22NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change0(0.00%)
Bid (Size)$62.00 (10)
Ask (Size)$73.08 (15)
Day Low / HighN/A - N/A
Volume795.0 K
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Blueprint Medicines Corp ( NASDAQ )

Price: $72.22
Change: +2.50 (3.59%)
Volume: 795.0 K
4:00PM ET 8/12/2022
 
 

Denali Therapeutics Inc ( NASDAQ )

Price: $38.11
Change: -0.37 (0.96%)
Volume: 718.5 K
4:00PM ET 8/12/2022
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $86.37
Change: +5.92 (7.36%)
Volume: 672.2 K
4:00PM ET 8/12/2022
 
 

Arrowhead Pharmaceuticals Inc ( NASDAQ )

Price: $47.29
Change: +1.66 (3.64%)
Volume: 604.0 K
4:00PM ET 8/12/2022
 
 

Fate Therapeutics Inc ( NASDAQ )

Price: $33.82
Change: +1.17 (3.58%)
Volume: 1.4 M
4:00PM ET 8/12/2022
 

Read more news Recent News

--SVB Securities Adjusts Blueprint Medicines' Price Target to $65 from $56, Maintains Market Perform Rating
10:23AM ET 8/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Goldman Sachs Raises Blueprint Medicines Price Target to $143 From $126, Maintains Buy Rating
9:07AM ET 8/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Raymond James Adjusts Blueprint Medicines' Price Target to $115 From $133, Keeps Strong Buy Rating
5:22AM ET 8/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Blueprint Medicines Reports Wider Q2 Loss as Revenue Advances, Full-Year Sales Guidance Unveiled
8:19AM ET 8/02/2022 MT Newswires

Blueprint Medicines (BPMC) on Tuesday reported a Q2 diluted loss of $2.68 per share, which was wider than the diluted loss of $1.86 per share registered...

Company Profile

Business DescriptionBlueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA. View company web site for more details
Address45 Sidney Street
Cambridge, Massachusetts 02139
Phone+1.617.374.7580
Number of Employees217
Recent SEC Filing08/10/20224
President, Chief Executive Officer & DirectorKathryn Haviland
Chief Operating OfficerChristina Rossi
Chief Financial OfficerMichael Landsittel
Senior Vice President-Technical OperationsChristopher K. Murray

Company Highlights

Price Open$70.24
Previous Close$69.72
52 Week Range$43.46 - 117.86
Market Capitalization$4.3 B
Shares Outstanding59.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/27/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$11.87
Beta vs. S&P 500N/A
Revenue$44.5 M
Net Profit Margin-304.41%
Return on Equity-72.95%

Analyst Ratings as of 07/09/2022

Buy
10
Overweight
1
Hold
4
Underweight
0
Sell
2
Consensus RecommendationConsensus Icon
Powered by Factset